HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free All Versions of this Article: 103/4/1438    most recent 00713.2007v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Behfar, A. Articles by Terzic, A. Search for Related Content PubMed PubMed Citation Articles by Behfar, A. Articles by Terzic, A.

INVITED REVIEW

HIGHLIGHTED TOPIC
Perspectives in Innate and Acquired Cardioprotection

Cardioprotective repair through stem cell-based cardiopoiesis

Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Molecular Pharmacology and Experimental Therapeutics, and Medical Genetics, Mayo Clinic, Rochester, Minnesota

Ischemic heart disease continues to progress at pandemic levels despite current preventive and therapeutic interventions. Recent advances in stem cell biology have provided the impetus for a paradigm shift in treatment options, potentially transforming palliative care into curative therapy. Although delivery of stem cells in clinical trials has resulted in a modest functional improvement of myocardial performance in the setting of infarction, ongoing efforts at the bench and bedside are taking place to increase stem cell propensity for engraftment and homing into diseased myocardium. The newest opportunity has arisen with the delivery of stem cells guided to execute the cardiac program. Here, we examine the recent application of genomic and proteomic technology to decipher the process of cardiopoiesis and to recruit cardiopoietic stem cells for cardioprotection and safe myocardial repair.

myocardial infarction; genomics; heart; proteomics; regenerative medicine

This article has been cited by other articles:

				S. Yamada, T. J. Nelson, R. J. Crespo-Diaz, C. Perez-Terzic, X.-K. Liu, T. Miki, S. Seino, A. Behfar, and A. Terzic Embryonic Stem Cell Therapy of Heart Failure in Genetic Cardiomyopathy Stem Cells, October 1, 2008; 26(10): 2644 - 2653. [Abstract] [Full Text] [PDF]